Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -51.73% is 65% above its 5-year average of -147.14%, near the high end of its 5-year range (-266.15%–-19.81%).
44.17% above its 12-month average of -92.66%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -19.81%.
NET PROFIT MARGIN
-51.73%
NET PROFIT MARGIN AVG TTM
-92.66%
NET PROFIT MARGIN AVG 3Y
-121.61%
NET PROFIT MARGIN AVG 5Y
-147.14%
NET PROFIT MARGIN AVG 10Y
-113.74%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+44.17%
CURRENT VS 3Y AVG
+57.46%
CURRENT VS 5Y AVG
+64.84%
CURRENT VS 10Y AVG
+54.52%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-19796.15%
vs the sector median at left
UroGen Pharma Ltd.
Market Cap
$2.02B
Net Profit Margin
-51.73%
TTM Avg
-92.66%
3Y Avg
-121.61%
5Y Avg
-147.14%
Market Cap
$2.02B
Net Profit Margin
100.84%
TTM Avg
51.96%
3Y Avg
-5.31%
5Y Avg
-103.82%
Market Cap
$2.02B
Net Profit Margin
-40.90%
TTM Avg
5.22%
3Y Avg
-37.29%
5Y Avg
-215.44%
Market Cap
$2.05B
Net Profit Margin
7.91%
TTM Avg
5.18%
3Y Avg
-0.36%
5Y Avg
-0.65%
Market Cap
$1.98B
Net Profit Margin
-3.18%
TTM Avg
-24.20%
3Y Avg
-10.68%
5Y Avg
-8.90%
Market Cap
$2.06B
Net Profit Margin
-268385.71%
TTM Avg
-9751.05%
3Y Avg
-6580.61%
5Y Avg
-4774.06%
Market Cap
$2.06B
Net Profit Margin
-544.06%
TTM Avg
-44935.33%
3Y Avg
-43227.84%
5Y Avg
-31022.63%
Market Cap
$1.97B
Net Profit Margin
15.03%
TTM Avg
11.31%
3Y Avg
2.06%
5Y Avg
-9.89%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.02B | -51.73% | -92.66% | -121.61% | -147.14% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 100.84% | 51.96% | -5.31% | -103.82% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | -40.90% | 5.22% | -37.29% | -215.44% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 6.00% | 4.60% | 4.69% | 7.56% |
| Vericel Corporation (VCEL)vs › | $2.05B | 7.91% | 5.18% | -0.36% | -0.65% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | -3.18% | -24.20% | -10.68% | -8.90% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -268385.71% | -9751.05% | -6580.61% | -4774.06% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -544.06% | -44935.33% | -43227.84% | -31022.63% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 15.03% | 11.31% | 2.06% | -9.89% |
| Alvotech (ALVO)vs › | $2.08B | -36.51% | -21.30% | -316.14% | -299.31% |
Operating Margin
-113.7%
Net Profit Margin
-51.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -19.81% |
| 2026-03-31 | -46.26% |
| 2025-12-31 | -69.68% |
| 2025-09-30 | -121.34% |
| 2025-06-30 | -206.24% |
| 2025-03-31 | -216.47% |
| 2024-12-31 | -152.71% |
| 2024-09-30 | -93.93% |
| 2024-06-30 | -152.89% |
| 2024-03-31 | -171.91% |
| 2023-12-31 | -110.57% |
| 2023-09-30 | -104.93% |
| 2023-06-30 | -114.18% |
| 2023-03-31 | -175.74% |
| 2022-12-31 | -159.57% |
| 2022-09-30 | -160.47% |
| 2022-06-30 | -160.75% |
| 2022-03-31 | -209.32% |
| 2021-12-31 | -175.91% |
| 2021-09-30 | -266.15% |
| 2021-06-30 | -201.21% |
| 2021-03-31 | -346.49% |
| 2020-12-31 | -383.20% |
| 2020-09-30 | -832.59% |
| 2020-06-30 | -8427.15% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -124872.22% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | -7255.48% |
| 2018-06-30 | -4952.20% |
| 2018-03-31 | -2782.12% |
| 2017-12-31 | -3078.59% |
| 2017-09-30 | -3.81% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | -17984.21% |
| 2016-12-31 | 70.17% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
